DEALS: Pfizer, Icagen ink development pact

DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Icagen

Development pact

Icagen stands to pocket up to $359 million in milestones for successful programs that target three sodium ion channels as a mechanism for controlling pain.

Sonic

Bioscientia

$256.4M buyout

Bioscientia has been acquired by Sonic Healthcare, which valued the company at €190 million.

Nektar Therapeutics

Bayer Healthcare

$225M licensing deal

Nektar Therapeutics is getting $50 million up front in a $175 million licensing deal for the successful development of a new therapy for severe pneumonia.

Archemix

Ophthotech

Licensing deal

Archemix granted Ophthotech worldwide rights to all ophthalmic uses of Archemix's proprietary aptamers targeting the C5 component of the complement cascade.